Preston W. Campbell, III, President and CEO to retire; Michael P. Boyle, MD, appointed as successor effective January 2020.
Site Search
The Cystic Fibrosis Foundation has announced the recipients of its first annual Impact Grants.
Carbon Biosciences is the first company to publicly launch from the Foundation’s collaboration with Longwood Fund and the first to work alongside CF Foundation researchers at the Foundation’s therapeutics lab
Barisic will transition from current role as Chief Financial and Administrative Officer in January 2023
President and CEO Michael Boyle shares a message to CF Foundation staff on racism and discrimination.
As I assume my new role as president and CEO of the CF Foundation, I am humbled by all that this organization has achieved and am determined to continue our work toward the ultimate goal. Here are my thoughts as I take over the reins from my dear friend and colleague.
Drug Targets the Underlying Cause of the Disease in People with the Most Common CF Mutation
Program Aimed at Advancing Search for Therapies Targeting Most Common Mutation of CF